- Home
- THTX vs NTHI Comparison
THTX vs NTHI Comparison
Compare THTX & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THTX
- NTHI
- Stock Information
- Founded
- THTX 1993
- NTHI 2008
- Country
- THTX Canada
- NTHI United States
- Employees
- THTX N/A
- NTHI N/A
- Industry
- THTX Biotechnology: Pharmaceutical Preparations
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- THTX Health Care
- NTHI Health Care
- Exchange
- THTX Nasdaq
- NTHI Nasdaq
- Market Cap
- THTX 144.8M
- NTHI 155.4M
- IPO Year
- THTX N/A
- NTHI N/A
- Fundamental
- Price
- THTX $3.29
- NTHI $9.97
- Analyst Decision
- THTX Hold
- NTHI
- Analyst Count
- THTX 1
- NTHI 0
- Target Price
- THTX N/A
- NTHI N/A
- AVG Volume (30 Days)
- THTX 372.3K
- NTHI 82.3K
- Earning Date
- THTX 10-09-2025
- NTHI 08-19-2025
- Dividend Yield
- THTX N/A
- NTHI N/A
- EPS Growth
- THTX N/A
- NTHI N/A
- EPS
- THTX N/A
- NTHI N/A
- Revenue
- THTX $84,378,000.00
- NTHI $59,990.00
- Revenue This Year
- THTX N/A
- NTHI N/A
- Revenue Next Year
- THTX $13.76
- NTHI N/A
- P/E Ratio
- THTX N/A
- NTHI N/A
- Revenue Growth
- THTX 2.19
- NTHI N/A
- 52 Week Low
- THTX $1.12
- NTHI $3.20
- 52 Week High
- THTX $3.31
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- THTX 70.36
- NTHI N/A
- Support Level
- THTX $3.26
- NTHI N/A
- Resistance Level
- THTX $3.31
- NTHI N/A
- Average True Range (ATR)
- THTX 0.02
- NTHI 0.00
- MACD
- THTX -0.00
- NTHI 0.00
- Stochastic Oscillator
- THTX 71.43
- NTHI 0.00
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").